Cargando…

The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic

The past two decades have seen important progress in access to timely, reliable, affordable, and quality-assured supplies of vaccines of global public health importance. The new vaccines developed are powerful tools to fight killers such as pneumonia, diarrhea, and cervical cancer. Global and region...

Descripción completa

Detalles Bibliográficos
Autores principales: Cernuschi, Tania, Malvolti, Stefano, Hall, Shanelle, Debruyne, Luc, Bak Pedersen, Hanne, Rees, Helen, Cooke, Emer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Health Organization. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585501/
http://dx.doi.org/10.1016/j.vaccine.2022.07.032
_version_ 1784813507253895168
author Cernuschi, Tania
Malvolti, Stefano
Hall, Shanelle
Debruyne, Luc
Bak Pedersen, Hanne
Rees, Helen
Cooke, Emer
author_facet Cernuschi, Tania
Malvolti, Stefano
Hall, Shanelle
Debruyne, Luc
Bak Pedersen, Hanne
Rees, Helen
Cooke, Emer
author_sort Cernuschi, Tania
collection PubMed
description The past two decades have seen important progress in access to timely, reliable, affordable, and quality-assured supplies of vaccines of global public health importance. The new vaccines developed are powerful tools to fight killers such as pneumonia, diarrhea, and cervical cancer. Global and regional financing and pooled procurement have shortened the lag between access in high- and lower-income countries. The COVID-19 pandemic has shown that by addressing shortcomings and seizing opportunities, we can do even more. In response to COVID-19, vaccine development and access shifted from a sequential, risk-averse paradigm to a rapid approach with maximum compression of time to market while ensuring quality. Vast public investments and innovative technologies were key facilitators. The pandemic has shown that governments play a crucial role in investing in new vaccines and manufacturing capacity and sharing risks with industry. Despite impressive progress, equity in access remains elusive with important moral, economic, and health-related consequences. Global leaders are working on a new International Treaty for Pandemic Prevention, Preparedness, and Response. To apply the lessons of COVID-19, that treaty should include a new paradigm for access to vaccines in which governments agree to: (1).. establish early sharing of information about emerging outbreaks and early, evidence-informed strategic goals and leadership that serve the collective global health interest. (2).. shoulder risks and invest aggressively to address the needs of today and prepare for future emergencies. (3).. strengthen market preparedness by investing in new vaccine technologies, regional research, development and manufacturing hubs, and insurance; by enabling regulatory harmonization; by driving market transparency and oversight; and by ensuring that where public funds are invested there is a contractual obligation to ensure access. (4).. define principles and operational details for collaboration in times of scarcity that enable countries to protect their own citizens while ensuring that no country is left behind. This would ensure that COVID-19 catalyzes a shift toward greater access for all under Immunization Agenda 2030.
format Online
Article
Text
id pubmed-9585501
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher World Health Organization. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-95855012022-10-21 The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic Cernuschi, Tania Malvolti, Stefano Hall, Shanelle Debruyne, Luc Bak Pedersen, Hanne Rees, Helen Cooke, Emer Vaccine Article The past two decades have seen important progress in access to timely, reliable, affordable, and quality-assured supplies of vaccines of global public health importance. The new vaccines developed are powerful tools to fight killers such as pneumonia, diarrhea, and cervical cancer. Global and regional financing and pooled procurement have shortened the lag between access in high- and lower-income countries. The COVID-19 pandemic has shown that by addressing shortcomings and seizing opportunities, we can do even more. In response to COVID-19, vaccine development and access shifted from a sequential, risk-averse paradigm to a rapid approach with maximum compression of time to market while ensuring quality. Vast public investments and innovative technologies were key facilitators. The pandemic has shown that governments play a crucial role in investing in new vaccines and manufacturing capacity and sharing risks with industry. Despite impressive progress, equity in access remains elusive with important moral, economic, and health-related consequences. Global leaders are working on a new International Treaty for Pandemic Prevention, Preparedness, and Response. To apply the lessons of COVID-19, that treaty should include a new paradigm for access to vaccines in which governments agree to: (1).. establish early sharing of information about emerging outbreaks and early, evidence-informed strategic goals and leadership that serve the collective global health interest. (2).. shoulder risks and invest aggressively to address the needs of today and prepare for future emergencies. (3).. strengthen market preparedness by investing in new vaccine technologies, regional research, development and manufacturing hubs, and insurance; by enabling regulatory harmonization; by driving market transparency and oversight; and by ensuring that where public funds are invested there is a contractual obligation to ensure access. (4).. define principles and operational details for collaboration in times of scarcity that enable countries to protect their own citizens while ensuring that no country is left behind. This would ensure that COVID-19 catalyzes a shift toward greater access for all under Immunization Agenda 2030. World Health Organization. Published by Elsevier Ltd. 2022-10-21 /pmc/articles/PMC9585501/ http://dx.doi.org/10.1016/j.vaccine.2022.07.032 Text en © 2022 World Health Organization. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Cernuschi, Tania
Malvolti, Stefano
Hall, Shanelle
Debruyne, Luc
Bak Pedersen, Hanne
Rees, Helen
Cooke, Emer
The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic
title The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic
title_full The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic
title_fullStr The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic
title_full_unstemmed The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic
title_short The quest for more effective vaccine markets – Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic
title_sort quest for more effective vaccine markets – opportunities, challenges, and what has changed with the sars-cov-2 pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585501/
http://dx.doi.org/10.1016/j.vaccine.2022.07.032
work_keys_str_mv AT cernuschitania thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT malvoltistefano thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT hallshanelle thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT debruyneluc thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT bakpedersenhanne thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT reeshelen thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT cookeemer thequestformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT cernuschitania questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT malvoltistefano questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT hallshanelle questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT debruyneluc questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT bakpedersenhanne questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT reeshelen questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic
AT cookeemer questformoreeffectivevaccinemarketsopportunitieschallengesandwhathaschangedwiththesarscov2pandemic